Dr. Jonathan Talbot is an experienced biotech executive and second-time CEO, building on more than 15 years in the pharmaceutical industry with expertise in strategy, clinical development and business development.
He was the Co-Founder and CEO of Mosanna Therapeutics, where he led the company through multiple financing rounds exceeding $85 million and advanced a novel nasal spray therapy for obstructive sleep apnea through preclinical development to MHRA approval for entry into clinical trials.
Previously, Jonathan spent nearly a decade at Roche, where he served in a broad range of roles. As Global Scientific Director he drove medical aspects of the clinical development, successful launch and marketing of several novel biologic therapies.
In Pharma Partnering he gained deep experience in deal making and valuation, contributing to numerous licensing and acquisition deals.
Jonathan holds a PhD in Pharmacy from King’s College London and a Master’s in Finance from ESCP Business School, bringing a unique blend of scientific and financial expertise to company building and investor engagement.
